Anti-TNF alpha in the treatment of ulcerative colitis: A valid approach for organ-sparing or an expensive option to delay surgery?

Table 1 Rate of colectomy after therapy with Infliximab

Ref.	RCT	Pts (w)	Tipe off disease	FU	Rate of colectomy in IFX Pts	Rate of colectomy in control Pts	P value
Rutgeerts et al[51] Sandborn et al[52]	Y	364 (IFX) 364 (control)	Moderate to severe UC	54 wk (ACT1)	9.5%	14.7%	< 0.05
				30 wk (ACT2)
Sands et al[53]	Y	8 (IFX) 3 (control)	Severe active steroid-refractory	2 wk	50%	100%	NS
Järnerot et al[25]	Y	24 (IFX) 21 (control)	Severe to moderate UC not responding to conventional therapy	3 mo	29.2%	66.7%	0.017
Gustavsson et al[54]	Y	24 (IFX) 21 (control)	Severe to moderate UC not responding to conventional therapy	36 mo	50%	76%	0.012
Aratari et al[56]	N	15 (IFX)	Severe steroid-refractory UC	26 mo	18%
Teisner et al[57]	N	52 (IFX)	Acute, severe and chronic refractory UC	22 mo	27%
Ferrante et al[58]	N	121 (IFX)	Acute severe refractory UC	33 mo	17%	-	-
Oussalah et al[59]	N	191 (IFX) Multicenter	UC	18 mo	18.8%	-	-
Desmond et al[60]	N	21 (IFX)	UC	14 mo	9.5%	-	-
Garcia-Planella et al[61]	N	22 (IFX)	UC	84 mo	27.3%	-	-

RCT: Randomized controlled trial; Pts: Patients; FU: Follow-up; IFX: Infliximab; UC: Ulcerative colitis; Y: Yes; N: Not.